Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer

A Pilot Study to Estimate the Efficacy of Moxibustion Stimulation at Abdominal Acupoints on Quality of Life in Cancer Patients Under Chemotherapy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02261571

Enrollment

Registered

2014-10-10

Start date

2014-10-31

Completion date

2015-09-30

Last updated

2014-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Most cancer patients experience multiple symptoms related to chemotherapy and use CAM (complementary and alternative medicine) as an adjunct to conventional treatment. Moxibustion is traditional Korean medical therapeutic method and uses the heat generated by burning herbal preparations containing Artemisia vulgaris to stimulated acupoint. Herein, the investigators propose an open-label pilot study investigating the effectiveness of moxibustion stimulation at abdominal acupoint on quality of life in cancer patients under chemotherapy.

Interventions

OTHERMoxibustion

In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion. The moxibustion will be removed when the patient feel hotness and require remove them

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnostic histopathology of cancer * Performance status of 0-2 on the European Cooperative Oncology Group (ECOG) performance scale. * Patients on chemotherapy currently have plan to receive chemotherapy for more than 6 weeks. * Follow-up possible during the clinical trial * Informed signed consent

Exclusion criteria

* Patients with Severe Heart disease and hypertension that is not controlled (systolic blood pressure \>160 or Diastolic blood pressure \>100) * Patients with diabetes that is not controlled (FBST \>180 or BST\>250) * Patients with abdominal injury or severe ascites can't be received moxibustion therapy on abdomen. * Hypersensitive section to moxibustion treatment * Inability to comprehend or express oneself in the Korean language * An Individual deemed to be ineligible by a physician * Refusal to participate in this trial or to provide informed consent.

Design outcomes

Primary

Measure	Time frame
functional Assessment of Cancer Therapy: General (FACT-G)	change from baseline to 6 weeks

Secondary

Measure	Time frame	Description
Body mass index	change from baseline to 6 weeks	—
immune function	change from baseline to 6 weeks	lymphocyte panel(CD3,4,8,19,26), WBC, Differential count
M.D, Anderson symptom Inventory (MDASI)	change from baseline to 6 weeks	—

Countries

South Korea

Contacts

Primary ContactHyun Jung Jung, KMD, Ph. D

koreancarmen@gmail.com+82537702082

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026